QUARTERLY REPORT Period January – September 2023 PEPTONIC Medical AB (publ) org nr 556776–3064 (www.spotlightstockmarket.com, ticker: PMED) GROUP 2023 THIRD QUARTER (Jul-Sep) 2023 FIRST NINE
Peptonic Medical AB (“Peptonic” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company”s shares listed on Spotlight Stock Market. A liquidity
Peptonic Medical (publ) today announced that Apotek Hjärtat is initiating sales of the company’s leading intimate care product VagiVital® AktivGel in most of its physical
Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests
Peptonic Medical (publ) (‘Peptonic’ eller ‘bolaget’) annonserar att bolaget tecknat avtal med Fermata Inc. för den japanska marknaden. Avtalet avser VagiVital®️ och Lunette®️. Avtalet gäller
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the company has entered into an agreement with fermata Inc. for the Japan market. The agreement
Peptonic Medical AB (publ) (“Peptonic” eller “Bolaget”) meddelar idag att man beslutat att utnyttja rätten att konvertera det lån om 7,5 Mkr som Bolaget upptog
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces today that it has decided to exercise the right to convert the loan of SEK 7.5
Stockholm, 14 maj 2020 – Peptonic Medical AB (publ) (’Peptonic’ eller ’Bolaget’) meddelar i dag att Bolagets kvartalsrapport kommer att publiceras senare under dagen.
Peptonic Medical AB (publ) årsredovisning för verksamhetsåret 2019 finns nu tillgänglig på sidan Financial information. Er tryckt kopia av årsredovisningen kan beställas via e-post info@peptonicmedical.se eller via
www.spotlightstockmarket.com, kortnamn: PMED 2019 kvartal 3 (jul-sep) Omsättning produkter 1 557 (120) KSEK Bruttovinst 692 (95) KSEK, 45% (79%) Rörelseresultat -4 127 (-3 420) KSEK
www.aktietorget.se ticker: PMED 2019 third quarter (Jul-Sep) Net sales of products KSEK 1,557 (120) Gross profit KSEK 692 (95), Gross margin 45% (79%) Operating loss
2019 kvartal 2 (apr-jun) Omsättning produkter 1 011 (0) KSEK Bruttovinst 768 (0) KSEK, 76% (0%) Rörelseresultat -5 102 (-3,563) KSEK Resultat per aktie -0,06
2019 first quarter (Apr-Jun) Net sales of products KSEK 1,011 (0) Gross profit KSEK 768 (0), Gross margin 76% (0%) Operating loss KSEK -5,102 (-3,563)
Basscenariot visar på en riktkurs om 1,40 kr, vilket är avsevärt högre än teckningskursen på 0,83 kr i den pågående företrädesemissionen. Läs hela artikeln på
PEPTONIC Medical (publ) (”PEPTONIC Medical eller ”Bolaget”) – meddelar att Analysguiden med anledning av den pågående företrädesemissionen har publicerat en ny analys av bolaget. Analysguiden
The Board of Directors of Peptonic Medical AB (publ) (Peptonic or Company) today announced the decision to commence the process of obtaining CE-marking for the
Tisdagen den 11 april arrangerade PEPTONIC medical ett informationsmöte med aktieägarna. På mötet berättade styrelse och ledning om den nyss slutförda fas IIb-studien och om planerna framåt.
Aktieägarna i Peptonic Medical bjuds härmed in till ett informationsmöte den 11 april kl 17-19. Mötet hålls på Scandic Klara, Slöjdgatan 7, Stockholm. Medverkande från
Peptonic Medical AB (publ) today announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel
Peptonic Medical AB (publ) (“the Company” or “Peptonic”) – a company developing pharmaceuticals based on oxytocin – today announced that 57 study subjects have been
Peptonic Medical (publ) – ett bolag som utvecklar läkemedel baserade på oxytocin – meddelar idag att sex veckor efter start av studien har 57 patienter
PEPTONIC medical (publ) (”Peptonic Medical eller ”Bolaget”) – ett bolag som utvecklar läkemedel baserade på oxytocin – meddelar att bolaget kommer att delta på Stora
PEPTONIC medical (publ) – ett bolag som utvecklar läkemedel baserade på oxytocin – kommer att delta på Småbolagsdagen i Stockholm den 8:e juni. Småbolagsdagen arrangeras
Aktieägarna i PEPTONIC medical AB (publ), org.nr 556776-3064 (”Bolaget”) kallas härmed till årsstämma torsdagen den 9 april 2015 kl. 16.30 i Gällöfsta Konferens lokaler, Biblioteksgatan
PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and
Idag noteras PEPTONIC Medical på AktieTorget och i samband med det har VD, Dan Markusson, intervjuats av Redeye. Titta på intervjun » Aktiens handelsbeteckning är
Peptonic har genomfört en riktad nyemission samt en spridningsemission under maj respektive juni månad som tillsammans tillför bolaget drygt 22 mkr före emissionskostnader. Efter de
PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO)
PEPTONIC medical today announces that, at the PEPTONIC medical Annual General Meeting on April 8th, Mrs Nadia Whittley was elected as a new member to
PEPTONIC medical (publ) today announced that the Annual General Meeting (AGM) on April 8th resolved to make the Company to a public company. In conjunction
PEPTONIC medical today announced that it has recruited Johan Inborr to lead the business development activities of the company on a consultancy basis. Johan is
PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement,
PEPTONIC medical today announced that it has completed the evaluation of different tube models and materials for use as primary packaging of VAGITOCIN® – the
PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician
PEPTONIC medical today announced that it met with the US Food and Drug Administration (FDA) earlier this month in a so called pre-IND meeting. The
PEPONIC medical has signed an agreement with Destum Partners in USA for support in finding suitable collaboration partners. By using a US based consulting company
PEPTONIC has started a collaboration with Clinartis in USA. Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with
A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of
A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation
PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This
